

1. Suomi V, Treeby B, Jaros J, **Mäkelä P**, Anttinen M, Saunavaara J, Sainio T, Kiviniemi A, Blanco R: Transurethral ultrasound therapy of the prostate in the presence of calcifications: a simulation study. *Med Phys.* 45: 4793-4805, 2018.
2. Anttinen M, Yli-Pietilä E, Suomi V, **Mäkelä P**, Sainio T, Saunavaara J, Eklund L, Blanco Sequeiros R, Taimen P, Boström PJ: Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. *Int J Hyperthermia.* 36: 915-925, 2019.
3. Anttinen M, **Mäkelä P**, Suomi V, Kiviniemi A, Saunavaara J, Sainio T, Horte A, Eklund L, Taimen P, Blanco Sequeiros R, Boström PJ: Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. *Scand J Urol.* 53: 295-302, 2019.
4. Anttinen M, **Mäkelä P**, Nurminen P, Yli-Pietilä E, Suomi V, Sainio T, Saunavaara J, Taimen P, Blanco Sequeiros R, Boström PJ: Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer. *Scand J Urol.* 54: 481-486, 2020.
5. Anttinen M, **Mäkelä P**, Viitala A, Nurminen P, Suomi V, Sainio T, Saunavaara J, Taimen P, Blanco Sequeiros R, Boström P: Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results. *Eur Urol Open Sci.* 22: 79-87, 2020.
6. **Mäkelä P**, Anttinen M, Suomi V, Steiner A, Saunavaara J, Sainio T, Horte A, Taimen P, Boström P, Blanco Sequeiros R: Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer. *Acta Radiol.* 62: 1687-1695, 2021.
7. Wright C, **Mäkelä P**, Anttinen M, Sainio T, Boström P, Blanco Sequeiros R: Fiducial markers and their impact on ablation outcome for patients treated with MR-guided transurethral ablation (TULSA): a retrospective technical analysis. *Int J Hyperthermia.* 38: 1677-1684, 2021.
8. Viitala A, Anttinen M, Wright C, Virtanen I, **Mäkelä P**, Hovinen T, Sainio T, Saunavaara J, Taimen P, Blanco Sequeiros R, Boström P: Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study. *BJU Int.* 129: 208-216, 2022.
9. **Mäkelä P**, Wright C, Anttinen M, Boström P, Blanco Sequeiros R: Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers. *Acta Radiol.* 64: 1228-1237, 2023.
10. Wright C, **Mäkelä P**, Bigot A, Anttinen M, Boström P, Blanco Sequeiros R: Deep learning prediction of non-perfused volume without contrast agents during prostate ablation therapy. *Biomed Eng Lett.* 13: 31-40, 2022.
11. **Mäkelä P**, Anttinen M, Wright C, Sainio T, Boström P, Blanco Sequeiros R: Evolution of non-perfused volume after transurethral ultrasound ablation of prostate: A retrospective 12-month analysis. *Eur J Radiol Open.* doi: 10.1016/j.ejro.2023.100506, 2023.

12. Anttinen M, **Mäkelä P**, Nurminen P, Pärssinen H, Malaspina S, Sainio T, Högerman M, Taimen P, Blanco Sequeiros R, Boström P. Salvage Magnetic Resonance Imaging–guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer. *Eur U Open Sci.* 71: 69-77, 2025.
13. Viitala A, Anttinen M, **Mäkelä P**, Pärssinen H, Nurminen P, Sainio T, Saunavaara J, Taimen P, Blanco Sequeiros R, Boström P. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study. *BJU Int.* Online ahead of print, 2025.